Stem cell factor (SCF) is a hematopoietic growth factor which acts on
both primitive and mature progenitors cells. In animals, high doses of
SCF alone stimulate increases in cells of multiple lineages and mobil
ize peripheral blood progenitor cells (PBPC). Phase I studies of rhSCF
have demonstrated dose related side effects which are consistent with
mast cell activation. Based upon in vitro synergy between SCF and G-C
SF we have demonstrated the potential of low doses of SCF to synergize
with G-CSF to give enhanced mobilization of PBPC. These PBPC have inc
reased potential for both short and long term engraftment in lethally
irradiated mice and lead to more rapid recovery of platelets. On going
Phase I/II studies with rhSCF plus rhG-CSF for mobilization of PBPC,
demonstrated similar increases in PBPC compared to rhG-CSF alone. Thes
e data suggest a clinical role of rhSCF in combination with rhG-CSF fo
r optimal mobilization of PBPC.